Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.06.005

Alejandro de Arriba Fernández , José Luis Alonso Bilbao , Alberto Espiñeira Francés , Antonio Cabeza Mora , Ángela Gutiérrez Pérez , Miguel Ángel Díaz Barreiros

{"title":"Epidemiological study of vaccination against SARS-CoV-2 and its impact on COVID-19 progression in a cohort of patients in gran Canaria","authors":"Alejandro de Arriba Fernández , José Luis Alonso Bilbao , Alberto Espiñeira Francés , Antonio Cabeza Mora , Ángela Gutiérrez Pérez , Miguel Ángel Díaz Barreiros","doi":"10.1016/j.vacun.2023.06.005","DOIUrl":"10.1016/j.vacun.2023.06.005","url":null,"abstract":"<div><h3>Objectives</h3><p>We analyzed the impact of age, sex, vaccination against COVID-19, immunosuppressive treatment, and comorbidities on patients' risk of requiring hospital admission or of death.</p></div><div><h3>Methods</h3><p>Population-based observational retrospective study conducted on a cohort of 19,850 patients aged 12 years or more, who were diagnosed with COVID-19 between June 1st and December 31st, 2021, in the island of Gran Canaria.</p></div><div><h3>Results</h3><p>Hypertension (18.5%), asthma (12.8%) and diabetes (7.2%) were the most frequent comorbidities; 147 patients died (0.7%). The combination of advanced age, male sex, cancer, coronary heart disease, immunosuppressive treatment, hospital admission, admission to the intensive care unit, mechanical ventilation and lack of complete COVID-19 vaccination or booster dose was strongly predictive of mortality (p < 0.05); 831 patients required hospital admission and it was more frequent in men, older age groups, and patients with cancer, diabetes, arterial hypertension, chronic obstructive pulmonary disease, congestive heart failure or immunosuppressive treatment. The COVID-19 vaccine booster dose was associated with a lower risk of death ([OR] 0.11, 95% CI 0.06–0.21, p < 0.05) or hospital admission ([OR] 0.36, 95% CI 0.29–0.46, p < 0.05).</p></div><div><h3>Conclusions</h3><p>Cancer, coronary heart disease, and immunosuppressive treatment were associated with increased COVID-19 mortality. More complete vaccination was associated with lower risk of hospital admission or death. Three doses of the SARS-CoV-2 vaccine were highly associated with the prevention of death and hospital admission in all age groups. These findings suggest that COVID-19 vaccination can help bring the pandemic under control.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1), the next medical revolution against cancer CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1)，抗癌的下一个医学革命

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.01.006

Ali Adel Dawood

{"title":"CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1), the next medical revolution against cancer","authors":"Ali Adel Dawood","doi":"10.1016/j.vacun.2023.01.006","DOIUrl":"10.1016/j.vacun.2023.01.006","url":null,"abstract":"<div><p><span><span><span>Despite advances in modern treatment, many cancers have evolved to bypass the immune system. The immune system either cannot perceive the tumor as foreign or the immune response is hindered. </span>Oncolytic viruses<span> are designed to infect and kill cancer cells<span>. A huge variety of oncolytic viruses<span><span> have been produced and tested over the last 30 years. The presence of 9 different virus strains in the cells (mouse) at the same time allowed the genes from the different strains to be rearranged via homologous recombination to generate unique chimeric daughter viruses. CHECKvacc is a genetically engineered oncolytic virus (CF33) that is equipped with the human </span>sodium iodide symporter<span> (hNIS) and an anti-PD-L1 antibody. The novel modified viruses will be examined as a monotherapy or in combination with </span></span></span></span></span>pembrolizumab to determine the safety and efficacy of the treatment regimens. The first patient was dosed in a phase 1 </span>clinical trial<span> to assess the treatment's safety in people with advanced solid tumors. The medicine will be administered either directly into the tumors or intravenously.</span></p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55179959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 immune response in adults post Measles-Rubella vaccination 成人麻疹-风疹疫苗接种后的COVID-19免疫反应

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.05.004

Suwoyo Suwoyo, Erna Rahma Yani, Koekoeh Hardjito

{"title":"COVID-19 immune response in adults post Measles-Rubella vaccination","authors":"Suwoyo Suwoyo, Erna Rahma Yani, Koekoeh Hardjito","doi":"10.1016/j.vacun.2023.05.004","DOIUrl":"https://doi.org/10.1016/j.vacun.2023.05.004","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to see how measles, mumps, and rubella vaccination affected the increase in SARS-CoV-2 immunoglobulin levels in individuals who had received the second dose of the SARS-CoV-2 vaccine.</p></div><div><h3>Material and method</h3><p>This research is a quasi-experimental type with a pre-post test design. The population studied were adults who had received the second dose of the SARS-CoV-2 vaccine, consisting of 30 people.</p></div><div><h3>Results</h3><p>The results of this study were that most (60%) research subjects experienced an increase in IgM and some subjects (46.6%) experienced an increase in anti-SARS-CoV-2 IgG levels. The administration of the MR vaccination had no effect on increasing anti-SARS-CoV-2 IgG and IgM levels. This happened because the increase in IgM and IgG levels in the pre and post-tests in most research subjects was relatively low.</p></div><div><h3>Conclusion</h3><p>The administration of the MR vaccine to adults who had received a second dose of the SARS-CoV-2 vaccine elicited a response with low levels of IgG and IgM SARS-CoV-2.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1576988723000365/pdfft?md5=b76809598cf6e41e652ab0d7bc117b12&pid=1-s2.0-S1576988723000365-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92146298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Fe de erratas de artículos publicados en la revista Vacunas 发表在《疫苗》杂志上的文章的勘误表

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.09.003

引用次数: 0

The impact of vaccination against monkeypox on risk of mpox reinfection 猴痘疫苗接种对麻疹再感染风险的影响

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.06.003

Farhad Dadgar , Jalil Rouhani , Fatemeh Dehghani , Masoud Keikha

引用次数: 0

Vacunación frente al SARS-CoV-2 en otoño de 2023: ¿a quién y cómo hay que vacunar? 2023年秋季SARS-CoV-2疫苗接种:给谁接种，如何接种?

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.08.001

Fernando Moraga-Llop , Magda Campins-Martí

引用次数: 0

Quince años de vacunación frente al virus del papiloma humano en España. Actualización 西班牙15年的人类乳头瘤病毒疫苗接种。更新

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.05.001

F. Moraga-Llop

引用次数: 0

ERX-41; Promising compound by targeting LIPA is a new Achilles heel therapeutic strategy for hard-to-treat solid tumors by induction of endoplasmic reticulum stress ERX-41;靶向LIPA的化合物是通过诱导内质网应激治疗难治性实体瘤的一个新的致命弱点

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.06.004

Majid Eslami , Mohammad Memarian , Bahman Yousefi

{"title":"ERX-41; Promising compound by targeting LIPA is a new Achilles heel therapeutic strategy for hard-to-treat solid tumors by induction of endoplasmic reticulum stress","authors":"Majid Eslami , Mohammad Memarian , Bahman Yousefi","doi":"10.1016/j.vacun.2023.06.004","DOIUrl":"10.1016/j.vacun.2023.06.004","url":null,"abstract":"<div><p>Recently there has been an incredible shift in cancer treatment, from broad-spectrum cytotoxic drugs<span><span> to targeted drugs known as small molecules and macromolecules. Although traditional therapies have been effective in cancer treatment, they often have adverse side effects due to their nonspecific action on both normal and tumor cells. The </span>endoplasmic reticulum<span> (ER), is known to control a variety of vital cellular processes, including protein production, folding/misfolding, and unfolding. The ER affects cell survival and death by activating the unfolded protein response<span><span> (UPR) if the balance is not preserved. Dysregulation of these pathways' homeostasis<span> in the ER is consequently linked to the emergence and development of cancer's pathological states. Therefore, targeting ER stress and ER stress-mediated apoptosis in </span></span>cancer cells<span> by small-molecule emerged as an intriguing unconventional approach that may be an effective strategy for treating cancers. This review attempts to introduce one of the newest small molecules known as ERX-41 for cancer has a poor clinical outcome strategy for solid tumors<span>, including breast, brain, pancreatic and ovarian cancer. ERX-41 induces ER stress resulting in cell death<span><span> through specific LIPA targeting. Importantly, demonstrated that ERX-41 activity is independent of LIPA lipase function but dependent on its ER localization. Mechanistically, ERX-41 binding of LIPA decreases expression of multiple ER-resident proteins involved in </span>protein folding<span> and induce ER stress. This molecules targeted approach has a large therapeutic window, with no adverse effects either on normal cells and leading of new Achilles heel discovery in the therapeutics development for multiple hard-to-treat solid tumors.</span></span></span></span></span></span></span></p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44439124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immuno-informatics design of a multimeric epitope peptide-based vaccine against dengue virus serotype-2 登革热病毒2型多聚表位肽疫苗的免疫信息学设计

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.04.001

Mohamed Sheik Tharik Abdul Azeeze , Rajaguru Arivuselvam

{"title":"Immuno-informatics design of a multimeric epitope peptide-based vaccine against dengue virus serotype-2","authors":"Mohamed Sheik Tharik Abdul Azeeze , Rajaguru Arivuselvam","doi":"10.1016/j.vacun.2023.04.001","DOIUrl":"10.1016/j.vacun.2023.04.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Dengue<span> viral infection<span> affects approximately 130 countries worldwide. According to WHO reports, 40% of the global population lives in rural areas with a high risk of contracting dengue. Researchers have identified four distant strains of the dengue virus, and a single vaccine has not permanently controlled the emergence of all four distant strains. Therefore, a vaccine is required for each of the four strains to address the current situation.</span></span></p></div><div><h3>Objectives</h3><p>The objective of this study was to design a multi-epitope-based vaccine for the dengue virus-2 strain that elicits a robust immune response while being safe and non-allergenic.</p></div><div><h3>Results</h3><p>Firstly, we analyzed the envelope protein<span> for its physicochemical and antigenic properties<span><span>. Next, we predicted MHC I, MHC II, and B-cell epitopes with high accuracy and evaluated their properties. Then, we constructed a vaccine using a suitable adjuvant and linkers, and predicted the secondary and tertiary structure of the vaccine, and the tertiary structure was validated. After conducting molecular docking with toll-like receptors, we utilized the best-docked result for molecular stimulation. Finally, we analyzed the </span>immune stimulation against the vaccine, and the results showed positive immune responses from macrophages, DC cells, T-cells, and B-cells. Additionally, we found that the vaccine was excreted from the human body.</span></span></p></div><div><h3>Conclusions</h3><p>Our study demonstrates the potential of using immunoinformatic tools and immunological knowledge to design a multi-epitope-based vaccine for the dengue virus-2 strain. This approach could be applied to designing vaccines for other diseases, and further studies are required to validate its effectiveness in vivo<em>.</em></p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44557931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the intention and hesitancy to receive a booster dose of COVID-19 vaccine among patients with comorbid disease conditions using a health belief model 利用健康信念模型探讨合并疾病患者接受新冠肺炎疫苗加强剂的意愿和犹豫

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.06.006

Anmar Al-Taie , Zekiye Yilmaz

{"title":"Exploring the intention and hesitancy to receive a booster dose of COVID-19 vaccine among patients with comorbid disease conditions using a health belief model","authors":"Anmar Al-Taie , Zekiye Yilmaz","doi":"10.1016/j.vacun.2023.06.006","DOIUrl":"10.1016/j.vacun.2023.06.006","url":null,"abstract":"<div><h3>Background</h3><p>Despite the fact that the WHO recommends that adults over the age of 18 have to receive a booster dose of the COVID-19 vaccine. The willingness and intention to accept a booster dose of the COVID-19 vaccine remain major issues among the general population, particularly patients with comorbid disease conditions. The aim of this study was to assess the patterns regarding COVID-19 infection and vaccination, along with the intention and hesitancy to receive a booster dose of the COVID-19 vaccine among patients with comorbid disease conditions in Istanbul, Türkiye.</p></div><div><h3>Methods</h3><p>This was a descriptive, cross-sectional study conducted among patients with comorbid disease conditions using a three-part, structured, validated questionnaire. Vaccine hesitancy from a booster dose of the COVID-19 vaccine was assessed using the Health Belief Model (HBM), based on a 5-point Likert-type scale.</p></div><div><h3>Results</h3><p>The study enrolled 162 participants with a mean age of 57.2 ± 13.3 years. 97% of the respondents received the COVID-19 vaccine. Almost half of respondents (51.2%) reported receiving information about a booster dose of the COVID-19 vaccine. HBM among the participants with comorbidities showed a significant agreement regarding the perceived susceptibility (P < 0.0001), perceived severity (P < 0.0001) and perceived benefits (P < 0.0001) to receive a booster vaccine dose. There was a statistically significant correlation between the intention to receive a booster vaccine dose and education level (university education; P < 0.0001).</p></div><div><h3>Conclusion</h3><p>A vast and significant majority of patients with chronic comorbid disease conditions who received the COVID-19 vaccine reported an intention to receive a booster dose.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1576988723000560/pdfft?md5=d3aefaf67debbc887f427846443ca254&pid=1-s2.0-S1576988723000560-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46180023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vacunas最新文献